Monday, January 14, 2019
Aslan target lowered to $8.50 from $12 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju lowered his price target for Aslan Pharmaceuticals to $8.50 after varlitinib data in first-line gastric cancer didn’t show statistical significance. The analyst, however, reiterates a Buy rating on the shares.
https://thefly.com/landingPageNews.php?id=2848037
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.